{"disease":{"id":"sle-systemic-lupus-erythematosus","name":"sle systemic lupus erythematosus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07087912","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":477,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT07136090","title":"OMERACT SLE Delphi","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07157202","title":"Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":115,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07077486","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03142711","title":"Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Lupus Research Alliance","has_results":false},{"nct_id":"NCT06925542","title":"A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"CRISPR Therapeutics","has_results":false},{"nct_id":"NCT07274059","title":"Allogeneic UCB-derived CAR-T for SLE","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chengdu Ucello Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07490041","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT07177911","title":"Safety and Efficacy Study of CC312 for Moderate to Severe SLE","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"CytoCares Inc","has_results":false},{"nct_id":"NCT06189157","title":"MB-CART19.1 in Refractory SLE","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT06839976","title":"CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT07266337","title":"CD19/BCMA CAR-T for SLE","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Chengdu Ucello Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07483346","title":"IASO-782 in Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shanghai IASO Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT07266090","title":"A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"Viatris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT07315087","title":"CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07193810","title":"A Study of CC312 for Relapsed/Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"CytoCares Inc","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}